Proactive leads the world in up-to-the-minute, multi-media news provision, events organisation, investor relations management and investor research Read more Proactive has always been a forward looking and enthusiastic technology adopter. About this content About the publisher Proactive news team spans the world's key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. The team delivers news and unique insights across the market including but not co ...

About Oliver Haill Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. ...

Group 1 - Proactive is a forward-looking company that embraces technology and automation, including generative AI, while ensuring all content is edited and authored by humans [2][5]. - The company operates a global network with bureaus and studios in major financial hubs such as London, New York, Toronto, Vancouver, Sydney, and Perth [4]. - Proactive's editorial team produces a significant volume of content, creating approximately 50,000 pieces of news, feature articles, and filmed interviews annually [3]. Group 2 - The financial news and online broadcast teams at Proactive focus on delivering fast, accessible, and actionable business and finance news to a global investment audience [6]. - Proactive covers a wide range of sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [7]. - The company’s content creators possess extensive expertise and experience, utilizing technology to enhance their workflows [8].

Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and... Read more Abou ...

Core Insights - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience, focusing on medium and small-cap markets as well as blue-chip companies and broader investment stories [1][2]. Group 1: Company Overview - Proactive has a global presence with bureaus and studios located in major finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2]. - The company specializes in delivering news and unique insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3]. Group 2: Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes, utilizing decades of expertise from its human content creators [4]. - The company occasionally employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans to maintain quality and best practices in content production [5].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [3][4] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [4]

Group 1 - Proactive is a leading provider of timely, multimedia news and investor relations management, focusing on delivering actionable business and finance news to a global audience [1][2] - The news team operates from key financial hubs including London, New York, Toronto, Vancouver, Sydney, and Perth, specializing in medium and small-cap markets while also covering blue-chip companies and broader investment stories [2][3] - Proactive covers a wide range of sectors, including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - The company emphasizes the use of technology to enhance workflows, adopting innovative tools and software to improve content delivery [4][5] - While Proactive utilizes automation and generative AI, all content is edited and authored by human experts to ensure quality and adherence to best practices [5]

Financial Performance - The company reported a net loss per common share for the three months ended March 31, 2024, with basic and diluted losses reflecting the weighted average number of shares outstanding during the period[33]. - As of March 31, 2024, accounts payable to TheraCour amounted to $213,148, a decrease from $233,434 as of June 30, 2023[38]. - The company has suspended the existing license requirement to maintain an advance with TheraCour until sufficient capital is raised, applying the existing advance of $500,000 towards current invoices[38]. - Total interest incurred under the unsecured convertible promissory note for the nine months ended March 31, 2024, was $49,808[42]. - As of March 31, 2024, the total property and equipment net value is $7,602,835, a decrease from $8,106,647 as of June 30, 2023, reflecting accumulated depreciation of $7,265,288[45]. - The Company’s intangible assets, net, amount to $327,376 as of March 31, 2024, down from $333,578 as of June 30, 2023, with amortization expense of $2,067 for the three months ended March 31, 2024[46]. - Accrued expenses totaled $258,795 as of March 31, 2024, compared to $143,760 as of June 30, 2023, with significant increases in clinical trial costs due to KMPL-related party[50]. - The company reported stockholders' equity of $10,651,570 as of March 31, 2024, compared to $8,149,808 as of June 30, 2023[226]. - Operating activities used approximately $4.8 million in cash during the nine months ended March 31, 2024, compared to $4.2 million in the same period of 2023[227]. Research and Development - Research and development costs charged by TheraCour for the three months ended March 31, 2024, were $588,763, compared to $622,016 for the same period in 2023[40]. - Clinical trial costs charged by KMPL for the three months ended March 31, 2024, were $77,435, while for the nine months ended March 31, 2024, these costs totaled $442,845[40]. - The company recorded a non-current liability and research and development expense of $1,500,000 related to a milestone payment due under the COVID-19 License Agreement[41]. - Research and development costs are aggregated across all projects, with a focus on COVID program drug candidates in the reported quarter[229]. Drug Development and Clinical Trials - NanoViricides, Inc. has completed Phase 1a/1b human clinical trials for its first drug candidate NV-CoV-2, with no reported adverse events and good tolerability at high dosing levels[75]. - The company plans to develop NV-387 as an ultra-broad-spectrum antiviral to treat various viral infections, including coronaviruses, RSV, and influenza, potentially covering all "tripledemic" viruses[76]. - NV-387 has shown superior efficacy in animal studies compared to existing therapeutics, significantly increasing lifespan in models infected with coronaviruses, RSV, smallpox, and influenza[86][87][88][89]. - NV-387 has shown positive results in Phase 1a/1b clinical trials, being well tolerated at the highest dose levels with no reported adverse events[100]. - The successful completion of Phase I trials for NV-387 positions the drug for advancement into Phase II efficacy trials, indicating a high probability of success[124]. - The company plans to initiate a Phase II clinical trial for NV-387 in India shortly after the Phase I report, with RSV and Influenza as potential indications[104]. - NV-387 has shown strong antiviral activity in pre-clinical studies, significantly outperforming Remdesivir in treating COVID-19[156]. - The company plans to advance NV-387 into clinical trials for RSV infection in pediatric patients, addressing an unmet medical need[160]. - A pre-IND application for NV-387 in RSV infection is being prepared, with plans to support it with non-clinical and Phase I clinical trial data[168]. - The company has successfully completed Phase 1 human clinical trials for the antiviral drug candidate NV-387 with no adverse events reported, indicating a high level of safety[200]. Market Potential and Strategy - The global RSV therapeutics market is projected to grow from $1.8 billion in 2022 to $8.73 billion by 2031, with a CAGR of 18.9%[96]. - The influenza market size is expected to increase from approximately $3.6 billion in 2021, with a CAGR of 8.5% from 2019 to 2032[97]. - The company is exploring partnerships for regulatory development and commercialization of its drug candidates, which may involve initial license fees and milestone payments[82]. - The company plans to develop NV-387 for additional indications, such as pediatric applications, to expand market penetration and improve return on investment[215]. - The company aims to secure non-dilutive funding for drug candidates that align with bio-defense and pandemic preparedness objectives[83]. Manufacturing and Production - The in-house cGMP-compliant manufacturing facility allows the company to produce clinical supplies efficiently, resulting in significant cost savings[120]. - The company has doubled its manufacturing capacity for NV-387 in preparation for Phase II/III clinical trials for RSV, ensuring sufficient supply[147]. - The company has established a cGMP-capable manufacturing facility designed to support the production of multi-kilogram-scale quantities of its nanoviricides drugs, including various formulations[205]. Intellectual Property and Regulatory - The company has filed two international PCT patent applications related to the TheraCour polymeric micelle technology for Coronavirus antiviral drugs, with expected patent expiry extending into 2043[223]. - The company is developing NV-HHV-1 for shingles treatment, with sufficient drug product manufactured for Phase I and II trials[193]. - The company is also developing a systemic drug for herpesvirus infections, expected to be superior to current acyclovir-related drugs[196]. - The company plans to seek non-dilutive funding for the development of NV-387 as a therapeutic for poxviruses under the FDA "Animal Rule"[189]. Financial Position and Funding - The company has limited experience with pharmaceutical drug development, which may affect budget estimates and timelines for drug development[211]. - The company intends to keep capital expenditures minimal to conserve cash for drug development purposes[210]. - As of March 31, 2024, the company had cash and cash equivalents of $3,257,240, an increase from $8,149,808 as of June 30, 2023[226].

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - NanoViricides has released new data supporting the safety and broad antiviral activity of its investigational therapeutic NV-387 against multiple viruses, including coronaviruses, RSV, and influenza A viruses [1][4] Group 1: Antiviral Efficacy - NV-387 demonstrated substantially superior antiviral effects in a lethal animal model of lung infection caused by Influenza A/H3N2 compared to three approved anti-influenza drugs: Oseltamivir, Peramivir, and Baloxivir [2] - The drug was effective against the orthopoxvirus family, including Smallpox and Mpox, in both inhalation and skin abrasion transmission modes [2] - In a model for Smallpox and Mpox infection, NV-387 increased the lifespan of mice comparably to the approved Smallpox drug tecovirimat [3] Group 2: Clinical Trials and Development - The company has completed Phase 1 clinical trials for NV-387 in healthy subjects with no adverse events, indicating safety for progression to Phase 2 [4] - NV-387 will advance into Phase 2 trials specifically for RSV, which currently has no treatment options [5] - The drug has shown superior efficacy in extending survival in animal models compared to existing approved drugs for influenza [5] Group 3: Strategic Importance - The development of NV-387 against Smallpox is significant due to concerns about the potential for viral escape from existing treatments like tecovirimat [6] - The combination of NV-387 and tecovirimat showed improved effects, suggesting a strong potential for developing a new drug against Smallpox [7] - The timeline for clinical trials is dependent on regulatory processes, although the company is prepared to proceed [8]